![]() ![]() Thyroid function deteriorated after the administration of ICM in 9/61 patients (15%). Results: Twenty-three (38%) of the 61 patients were given a prophylactic treatment. The difference between their thyroid function at the baseline and 11-30 days after the ICM-related procedure was considered the principal endpoint. Patients were given one of two different prophylactic treatments (methimazole alone or both methimazole and sodium perchlorate) or no prophylactic treatment. We included patients with available records of thyroid function tests performed before and after ICM were administered, who were at high risk of developing ICMIH. ![]() Materials and methods: We performed a longitudinal retrospective study on 61 patients admitted to a tertiary-level cardiology unit for diagnostic and/or therapeutic ICM-procedures. We also aimed to identify possible risk factors for the onset of ICMIH. We ran a cost analysis to ascertain the most cost-effective prophylactic treatment protocol. Although hyperthyroidism may have clinically relevant effects, whether high-risk patients should receive prophylactic treatment before they are administered ICM is still debated.Īim of the study: We aimed to demonstrate the safety and efficacy of prophylactic treatment with sodium perchlorate and/or methimazole to prevent ICM-induced hyperthyroidism (ICMIH) in a population of high-risk cardiac patients. Introduction: The use of iodinated contrast media (ICM) can lead to thyrotoxicosis, especially in patients with risk factors, such as Graves’ disease, multinodular goiter, older age, and iodine deficiency. ![]()
0 Comments
Leave a Reply. |